Anti-Restenosis After AMI by Erythropoietin
Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI)
1 other identifier
interventional
72
1 country
1
Brief Summary
The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2007
CompletedFirst Posted
Study publicly available on registry
January 17, 2007
CompletedJanuary 17, 2007
January 1, 2007
January 16, 2007
January 16, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
In-stent Neointimal volume
In-stent Late lumen loss
Semi-Quantitative evaluation of infarcted size of myocardium
Secondary Outcomes (6)
left ventricular end diastolic volume
left ventricular end systolic volume
left ventricular ejection fraction
left ventricular wall motion index
binary restenosis
- +1 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of acute myocardial infarction within 12hrs of symptom onset.
- Succeeded reperfusion due to primary PCI accomplished bare metal stent
You may not qualify if:
- Patients with cardiogenic shock (e.g. systolic BP\<80mmHg,use of catecholamine, use of IABP)
- Patients with anemia required transfusion
- Patients who are unwilling or unable to comply with the trial protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566, Japan
Related Publications (2)
Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, Matsunaga S, Tateishi K, Nomura T, Takahashi T, Tatsumi T, Matsubara H. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006 Jun 9;98(11):1405-13. doi: 10.1161/01.RES.0000224117.59417.f3. Epub 2006 Apr 27.
PMID: 16645141BACKGROUNDTaniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Nakamura T, Matsubara H. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J. 2010 Nov;74(11):2365-71. doi: 10.1253/circj.cj-10-0267. Epub 2010 Sep 8.
PMID: 20834185DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Hiroaki Matsubara, M.D., Ph.D.
Kyoto Prefectural University of Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
January 16, 2007
First Posted
January 17, 2007
Last Updated
January 17, 2007
Record last verified: 2007-01